Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...

Team Gleason has expanded its collaboration with Stentrode developer Synchron to help teach people about brain-computer ...

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...

The number of ALS cases in the U.S. is expected to increase by over 10% by 2030, as compared with 2022 prevalence rates, per ...

In her husband's nearly 15 years of living with ALS, columnist Kristin Neva sees pre- and post-diagnosis papers as a bittersweet treasure.

After columnist Dagmar Munn was diagnosed with ALS, she began setting an intention for the new year instead of formal resolutions.